Lipid-Related Markers and Cardiovascular Disease Prediction

E. di Angelantonio; P. Gao; L. Pennells; D. Kromhout

doi:10.1001/jama.2012.6571

Lipid-Related Markers and Cardiovascular Disease Prediction

E. di Angelantonio, P. Gao, L. Pennells, D. Kromhout

Research output: Contribution to journal › Article › Academic › peer-review

492 Citations (Scopus)

Abstract

Context The value of assessing various emerging lipid-related markers for prediction of first cardiovascular events is debated. Objective To determine whether adding information on apolipoprotein B and apolipoprotein A-I, lipoprotein(a), or lipoprotein-associated phospholipase A2 to total cholesterol and high-density lipoprotein cholesterol (HDL-C) improves cardiovascular disease (CVD) risk prediction. Design, Setting, and Participants Individual records were available for 165 544 participants without baseline CVD in 37 prospective cohorts (calendar years of recruitment: 1968-2007) with up to 15 126 incident fatal or nonfatal CVD outcomes (10 132 CHD and 4994 stroke outcomes) during a median follow-up of 10.4 years (interquartile range, 7.6-14 years). Man Outcome Measures Discrimination of CVD outcomes and reclassification of participants across predicted 10-year risk categories of low (

Original language	English
Pages (from-to)	2499-2506
Journal	JAMA: The Journal of the American Medical Association
Volume	307
Issue number	23
DOIs	https://doi.org/10.1001/jama.2012.6571
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

coronary-heart-disease
non-hdl cholesterol
myocardial-infarction
apolipoprotein-b
ldl cholesterol
a-i
risk
lipoprotein(a)
metaanalysis
prevention

Access to Document

10.1001/jama.2012.6571

Cite this

@article{7ca19f3189e24fb1a132aa33b4182633,

title = "Lipid-Related Markers and Cardiovascular Disease Prediction",

abstract = "Context The value of assessing various emerging lipid-related markers for prediction of first cardiovascular events is debated. Objective To determine whether adding information on apolipoprotein B and apolipoprotein A-I, lipoprotein(a), or lipoprotein-associated phospholipase A2 to total cholesterol and high-density lipoprotein cholesterol (HDL-C) improves cardiovascular disease (CVD) risk prediction. Design, Setting, and Participants Individual records were available for 165 544 participants without baseline CVD in 37 prospective cohorts (calendar years of recruitment: 1968-2007) with up to 15 126 incident fatal or nonfatal CVD outcomes (10 132 CHD and 4994 stroke outcomes) during a median follow-up of 10.4 years (interquartile range, 7.6-14 years). Man Outcome Measures Discrimination of CVD outcomes and reclassification of participants across predicted 10-year risk categories of low (",

keywords = "coronary-heart-disease, non-hdl cholesterol, myocardial-infarction, apolipoprotein-b, ldl cholesterol, a-i, risk, lipoprotein(a), metaanalysis, prevention",

author = "\{di Angelantonio\}, E. and P. Gao and L. Pennells and D. Kromhout",

year = "2012",

doi = "10.1001/jama.2012.6571",

language = "English",

volume = "307",

pages = "2499--2506",

journal = "JAMA: The Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "23",

}

TY - JOUR

T1 - Lipid-Related Markers and Cardiovascular Disease Prediction

AU - di Angelantonio, E.

AU - Gao, P.

AU - Pennells, L.

AU - Kromhout, D.

PY - 2012

Y1 - 2012

N2 - Context The value of assessing various emerging lipid-related markers for prediction of first cardiovascular events is debated. Objective To determine whether adding information on apolipoprotein B and apolipoprotein A-I, lipoprotein(a), or lipoprotein-associated phospholipase A2 to total cholesterol and high-density lipoprotein cholesterol (HDL-C) improves cardiovascular disease (CVD) risk prediction. Design, Setting, and Participants Individual records were available for 165 544 participants without baseline CVD in 37 prospective cohorts (calendar years of recruitment: 1968-2007) with up to 15 126 incident fatal or nonfatal CVD outcomes (10 132 CHD and 4994 stroke outcomes) during a median follow-up of 10.4 years (interquartile range, 7.6-14 years). Man Outcome Measures Discrimination of CVD outcomes and reclassification of participants across predicted 10-year risk categories of low (

AB - Context The value of assessing various emerging lipid-related markers for prediction of first cardiovascular events is debated. Objective To determine whether adding information on apolipoprotein B and apolipoprotein A-I, lipoprotein(a), or lipoprotein-associated phospholipase A2 to total cholesterol and high-density lipoprotein cholesterol (HDL-C) improves cardiovascular disease (CVD) risk prediction. Design, Setting, and Participants Individual records were available for 165 544 participants without baseline CVD in 37 prospective cohorts (calendar years of recruitment: 1968-2007) with up to 15 126 incident fatal or nonfatal CVD outcomes (10 132 CHD and 4994 stroke outcomes) during a median follow-up of 10.4 years (interquartile range, 7.6-14 years). Man Outcome Measures Discrimination of CVD outcomes and reclassification of participants across predicted 10-year risk categories of low (

KW - coronary-heart-disease

KW - non-hdl cholesterol

KW - myocardial-infarction

KW - apolipoprotein-b

KW - ldl cholesterol

KW - a-i

KW - risk

KW - lipoprotein(a)

KW - metaanalysis

KW - prevention

U2 - 10.1001/jama.2012.6571

DO - 10.1001/jama.2012.6571

M3 - Article

SN - 0098-7484

VL - 307

SP - 2499

EP - 2506

JO - JAMA: The Journal of the American Medical Association

JF - JAMA: The Journal of the American Medical Association

IS - 23

ER -

Lipid-Related Markers and Cardiovascular Disease Prediction

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this